Background Interleukin 2 receptor antagonists (IL2Ra) are used as induction therapy for
prophylaxis against acute rejection in kidney transplant recipients. Use of IL2Ra has …

Background Kidney transplantation is the therapy of choice for many patients with end‐stage
kidney disease (ESKD) with an improvement in survival rates and satisfactory short term …

Background Non-nephrotoxic immunosuppressive strategies that allow reduction of
calcineurin-inhibitor exposure without compromising safety or efficacy remain a goal in …

The Symphony study showed that at 1 year posttransplant, a regimen based on daclizumab
induction, 2 g mycophenolate mofetil (MMF), low-dose tacrolimus and steroids resulted in …

Safety and efficacy of two sirolimus (SRL)-based regimens were compared with tacrolimus
(TAC) and mycophenolate mofetil (MMF). Renal transplantation recipients were randomized …

As part of the Spare-the-Nephron trial, we evaluated the combination mycophenolate mofetil
(MMF) and sirolimus (SRL) as a calcineurin inhibitor (CNI)-free regimen for the preservation …

Background Calcineurin inhibitors (CNI) can reduce acute transplant rejection and
immediate graft loss but are associated with significant adverse effects such as hypertension …

In kidney transplantation, conversion to mammalian target of rapamycin (mTOR) inhibitors
may avoid calcineurin inhibitor (CNI) nephrotoxicity, but its impact on post‐transplant allo …

Background A systematic review and meta-analysis were performed to investigate the
efficacy and safety of conversion from calcineurin inhibitors (CNIs) to mammalian target of …

Calcineurin inhibitors improve acute rejection rates and short-term graft survival in renal
transplantation, but their continuous use may be deleterious. We evaluated the 5-year …